AC220 for Children With Relapsed/Refractory ALL or AML
Status:
Completed
Trial end date:
2013-09-12
Target enrollment:
Participant gender:
Summary
This is a phase I study of the investigational drug AC220 combined with cytarabine and
etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute
myelogenous leukemia (AML).
Phase:
Phase 1
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium